Aura Biosciences, Inc.
AURA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001501796
No open-market purchases or sales by Aura Biosciences, Inc. insiders were filed in the last 90 days; 146 institutions reported holding it in 13F filings for Q2 2026, worth $677.2M in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Aura Biosciences, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 117
- +11 vs. Q3 2025
- Shares held
- 50.2M
- −1.41M (−2.7%) vs. Q3 2025
- Total value
- $273.8M
- −$45.4M (−14.2%) vs. Q3 2025
- New holders
- 19
- 34 more added
- Sold out
- 8
- 38 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AURA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 146 | $677.2M |
| Q1 2026 | 126 | $340.3M |
| Q4 2025 | 117 | $273.8M |
| Q3 2025 | 106 | $319.2M |
| Q2 2025 | 105 | $316.9M |
| Q1 2025 | 94 | $231.5M |
| Q4 2024 | 94 | $324.3M |
| Q3 2024 | 81 | $329.2M |
| Q2 2024 | 75 | $300.4M |
| Q1 2024 | 78 | $307.1M |
| Q4 2023 | 72 | $327.8M |
| Q3 2023 | 64 | $254.4M |
| Q2 2023 | 59 | $334.4M |
| Q1 2023 | 57 | $232.6M |
| Q4 2022 | 49 | $250.0M |
| Q3 2022 | 43 | $295.7M |
| Q2 2022 | 44 | $223.8M |
| Q1 2022 | 34 | $298.8M |
| Q4 2021 | 32 | $220.1M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Aura Biosciences, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Regency Capital Management Inc. | 538,584 | $2.94M | 1.22% | −74,105−12.1% | Reduced |
| B Group, Inc. | 572,576 | $3.12M | 2.31% | 00.0% | Unchanged |
| Acorn Capital Advisors, LLC | 595,744 | $3.25M | 1.10% | 00.0% | Unchanged |
| Millennium Management LLC | 617,338 | $3.36M | 0.00% | +432,117+233.3% | Added |
| State Street Corp | 926,534 | $5.05M | 0.00% | +47,663+5.4% | Added |
| Levin Capital Strategies, L.P. | 1,035,586 | $5.64M | 0.49% | −591,688−36.4% | Reduced |
| Geode Capital Management, LLC | 1,255,450 | $6.85M | 0.00% | −2,497−0.2% | Reduced |
| Nantahala Capital Management, LLC | 2,117,697 | $11.5M | 0.69% | 00.0% | Unchanged |
| Franklin Resources Inc | 2,198,423 | $12.0M | 0.00% | −4920.0% | Reduced |
| Vanguard Group Inc | 2,936,538 | $16.0M | 0.00% | +46,035+1.6% | Added |
| Medicxi Ventures Management (Jersey) Ltd | 3,039,892 | $16.6M | 1.98% | 00.0% | Unchanged |
| BlackRock, Inc. | 3,560,424 | $19.4M | 0.00% | +154,947+4.5% | Added |
| Suvretta Capital Management, LLC | 4,372,884 | $23.8M | 0.59% | 00.0% | Unchanged |
| Long Focus Capital Management, LLC | 4,619,582 | $25.2M | 1.25% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 4,881,125 | $26.6M | 0.04% | 00.0% | Unchanged |
| Frazier Life Sciences Management, L.P. | 5,100,000 | $27.8M | 0.75% | 00.0% | Unchanged |
| Matrix Capital Management Company, LP | 6,922,870 | $37.7M | 65.48% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 0 | $0 | 0.00% | −584,849−100.0% | Sold out |
| Caligan Partners LP | 0 | $0 | 0.00% | −227,174−100.0% | Sold out |
| HighVista Strategies LLC | 0 | $0 | 0.00% | −27,174−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −25,356−100.0% | Sold out |
| Occudo Quantitative Strategies LP | 0 | $0 | 0.00% | −19,472−100.0% | Sold out |
| Water Island Capital LLC | 0 | $0 | 0.00% | −10,372−100.0% | Sold out |
| Quadrant Capital Group LLC | 0 | $0 | 0.00% | −87−100.0% | Sold out |
| Nisa Investment Advisors, LLC | 0 | $0 | 0.00% | −36−100.0% | Sold out |